trending Market Intelligence /marketintelligence/en/news-insights/trending/FCAOBQdGX6ChqgBzbb0-Xw2 content esgSubNav
In This List

US FDA approves Relmada's application for antidepressant drug

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


US FDA approves Relmada's application for antidepressant drug

Relmada Therapeutics Inc. said the U.S. FDA cleared the company's investigational new drug application for d-Methadone, its novel, N-methyl-D-aspartate receptor antagonist.

D-Methadone is a rapid acting, oral agent for the treatment of depression, neuropathic pain and other potential central nervous system pathological conditions.

The company can now advance the development program for d-Methadone to a phase 2a proof-of-concept clinical study in patients with treatment-resistant depression.